alexa Abstract | Advances in the development of antitumor monoclonal antibodies (mAbs) in China: A bibliometric examination

Journal of Chemical and Pharmaceutical Research
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Original Articles Open Access


Among the public health problems, cancer becomes the leading cause of deaths in China. As a new era in cancer therapy, monoclonal antibodies (mAbs) have increasingly attracted research and innovation attention. This paper uses bibliometric analysis to profile the research patterns of antitumor mAbs in China and make a comparison with the other eight developed countries. The results indicate that China has made a great progress in recent years and the number of publications of antitumor mAbs has reached the second position in the world since 2012. However, China’s low-cited articles, low h-index and lack of presence in highly influential global journals could prove to be limiting factors. The funding is mainly from government in China while for Big 8 countries, pharmaceutical companies are the main source. Chinese pharmaceutical companies should strengthen cooperation with universities. Only in this way, antitumor mAbs in China would really usher big development, not only in publication.

Author(s): Liang Wang and MaoYu Zhang


antitumor, monoclonal antibodies, mAb, bibliometric, China, antibodies

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us